Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GNC-039

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biokin Pharma

Drug class:

PD-L1 inhibitor, CD3 agonist, CD137 agonist, EGFRvIII inhibitor

Related drugs:

Undisclosed EGFRvIII-targeted alpha therapy (1)

atezolizumab (236)

durvalumab (200)

benmelstobart (12)

sugemalimab (7)

envafolimab (6)

imsapepimut and etimupepimut, adjuvanted (4)

socazolimab (2)

atezolizumab and hyaluronidase-tqjs (1)

cosibelimab-ipdl (1)

adebrelimab (0)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

linvoseltamab (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

ALG.APV-527 (1)

PF-08046049 (1)

PF-05082566 (1)

Undisclosed EGFRvIII-targeted alpha therapy (1)

›